Alicaforsen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Alicaforsen
Accession Number
DB06224
Type
Small Molecule
Groups
Investigational
Description
Not Available
Synonyms
  • ISIS-2302
Product Ingredients
IngredientUNIICASInChI Key
Alicaforsen Sodium4TWN6SZB8W331257-52-4Not applicable
Categories
UNII
J8435V445B
CAS number
185229-68-9
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in crohn's disease and ulcerative colitis.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Alicaforsen selectively inhibits ICAM‑1 gene expression. Over-expression of ICAM‑1 occurs in a wide variety of inflammatory disorders, including ulcerative colitis (UC), pouchitis and tissues in the eye, gastrointestinal teact, lungs and skin. UC is an inflammatory bowel disease of the colon, a part of the large intestine, and pouchitis is an inflammation of the surgically constructed internal pouch created in UC patients when their diseased colons are removed. [ISIS Pharmaceutical Website] Alicaforsen is a RNase H dependent phosphorothioate-modified antisense oligodeoxynucleotide inhibitor which shuts down specific sequences of intracellular adhesion molecule 1 (ICAM1) mRNA and thus production of ICAM1, which prevents the inflammatory response. ICAM is a cell surface glycoprotein (immunoglobulin superfamily) which facilitates leukocyte adhesion and antigen presentation in the intestinal mucosa. Alicaforsen hybridizes the oligonucleotide strand with the target mRNA to suppress expression of ICAM1.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Alicaforsen.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Alicaforsen.Investigational
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alicaforsen.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alicaforsen.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Alicaforsen.Approved
FingolimodAlicaforsen may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Alicaforsen.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Alicaforsen.Investigational
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Alicaforsen.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Alicaforsen.Approved, Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Alicaforsen.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Alicaforsen.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Alicaforsen is combined with Leflunomide.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Alicaforsen is combined with Natalizumab.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alicaforsen.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Alicaforsen is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Alicaforsen.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Alicaforsen.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Alicaforsen.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Alicaforsen.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Alicaforsen.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Alicaforsen.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Alicaforsen.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Alicaforsen.Investigational
TacrolimusTacrolimus may increase the immunosuppressive activities of Alicaforsen.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Alicaforsen.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Alicaforsen.Investigational
TofacitinibAlicaforsen may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Alicaforsen.Approved, Investigational
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Alicaforsen.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Alicaforsen.Approved
Food Interactions
Not Available

References

General References
  1. Miner PB Jr, Geary RS, Matson J, Chuang E, Xia S, Baker BF, Wedel MK: Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther. 2006 May 15;23(10):1427-34. [PubMed:16669957]
  2. Gewirtz AT, Sitaraman SV: Technology evaluation: alicaforsen (Isis). Curr Opin Mol Ther. 2005 Jun;7(3):273-81. [PubMed:15977426]
  3. Fefferman DS, Farrell RJ: Making sense of antisense: ISIS 2302 (alicaforsen) in the treatment of pouchitis. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchits. Inflamm Bowel Dis. 2004 Jul;10(4):487-8. [PubMed:15475766]
  4. Link [Link]
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentUlcerative Colitis (UC)2
3CompletedTreatmentCrohn's Disease (CD)1
3RecruitingTreatmentPouchitis1
3Unknown StatusTreatmentCrohn's Disease (CD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on March 19, 2008 10:17 / Updated on January 05, 2018 13:26